GlassScriptPhysician profile
Sara Springer
NPI 1104186345
$2,401.38
in general payments reported to CMS, 2019-2025
29 companies · $876 in 2025
The $876 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $615 · 2022: $255 · 2023: $333 · 2024: $322 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.40 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $287.76 | 2021-2025 | Farxiga |
| Glaxosmithkline, LLC. | $252.82 | 2021-2025 | Benlysta |
| Jazz Pharmaceuticals INC. | $204.45 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.31 | 2021-2025 | Jardiance |
| Medtronic, INC. | $133.70 | 2025 | Symplicity G3 |
| Daiichi Sankyo INC. | $125.00 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $120.98 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $120.70 | 2023-2025 | Jynarque |
| Vantive US Healthcare LLC | $117.17 | 2025 | Renal - Pd |
| Novo Nordisk INC | $107.87 | 2025 | Ozempic |
| Fresenius USA Marketing, INC. | $100.99 | 2024-2025 | Velphoro, Optiflux, Crit-Line |
| Amgen INC. | $93.52 | 2024-2025 | Tavneos |
| Travere Therapeutics, INC. | $88.76 | 2024-2025 | Thiola |
| Genzyme Corporation | $60.07 | 2021 | |
| Vifor Pharma, INC. | $54.25 | 2023 | Korsuva, Veltassa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.35 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.52 | 2021 | |
| Calliditas Therapeutics US INC. | $38.55 | 2025 | Tarpeyo |
| Genentech USA, INC. | $32.31 | 2021 | |
| Pfizer INC. | $32.16 | 2021-2024 | |
| Ardelyx, INC. | $31.37 | 2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $24.49 | 2021 | |
| Grifols USA, LLC | $22.80 | 2022 | |
| Akebia Therapeutics INC | $20.88 | 2025 | Vafseo |
| Scpharmaceuticals INC. | $19.11 | 2025 | |
| Aurinia Pharma U.S., INC. | $17.95 | 2025 | Lupkynis |
| Seqirus USA INC | $17.08 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.